UA103791C2 - Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу - Google Patents
Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозуInfo
- Publication number
- UA103791C2 UA103791C2 UAA201110844A UAA201110844A UA103791C2 UA 103791 C2 UA103791 C2 UA 103791C2 UA A201110844 A UAA201110844 A UA A201110844A UA A201110844 A UAA201110844 A UA A201110844A UA 103791 C2 UA103791 C2 UA 103791C2
- Authority
- UA
- Ukraine
- Prior art keywords
- methods
- tuberculosis
- compositions
- prevention
- management
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 201000008827 tuberculosis Diseases 0.000 title abstract 2
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15146709P | 2009-02-10 | 2009-02-10 | |
| PCT/US2010/023533 WO2010093588A1 (en) | 2009-02-10 | 2010-02-09 | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA103791C2 true UA103791C2 (uk) | 2013-11-25 |
Family
ID=42077260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201110844A UA103791C2 (uk) | 2009-02-10 | 2010-02-09 | Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20120149716A1 (https=) |
| EP (2) | EP2395995A1 (https=) |
| JP (2) | JP2012517441A (https=) |
| KR (1) | KR20110116049A (https=) |
| CN (1) | CN102387798A (https=) |
| AP (1) | AP3437A (https=) |
| AU (1) | AU2010213936B2 (https=) |
| BR (1) | BRPI1007500A2 (https=) |
| CA (1) | CA2750123A1 (https=) |
| CO (1) | CO6410289A2 (https=) |
| CR (1) | CR20110411A (https=) |
| EA (1) | EA201171035A1 (https=) |
| EC (1) | ECSP11011295A (https=) |
| HK (1) | HK1205681A1 (https=) |
| IL (1) | IL214176A (https=) |
| MX (1) | MX2011008132A (https=) |
| MY (1) | MY160002A (https=) |
| NI (1) | NI201100154A (https=) |
| NZ (1) | NZ594193A (https=) |
| PE (2) | PE20120580A1 (https=) |
| SG (2) | SG173149A1 (https=) |
| UA (1) | UA103791C2 (https=) |
| WO (1) | WO2010093588A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6143675B2 (ja) | 2010-12-16 | 2017-06-07 | セルジーン コーポレイション | 難溶性薬物の制御放出経口剤形及びその使用 |
| RU2627471C2 (ru) | 2011-09-14 | 2017-08-08 | Селджин Корпорейшн | Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты |
| RS60415B1 (sr) | 2011-12-27 | 2020-07-31 | Amgen (Europe) GmbH | Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona |
| WO2013119607A2 (en) * | 2012-02-08 | 2013-08-15 | Celgene Corporation | Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| WO2017070291A1 (en) * | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
| DE102018201827A1 (de) * | 2017-02-28 | 2018-08-30 | Aktiebolaget Skf | Wälzlager |
| CN112220785B (zh) * | 2020-09-22 | 2021-12-31 | 北京鑫开元医药科技有限公司 | 一种pde4抑制剂药物组合物及其制备方法与用途 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| IT1276040B1 (it) * | 1993-07-27 | 1997-10-24 | Angelini Francesco Ist Ricerca | Uso della benzidamina nel trattamento di stati patologici causati dal tnf |
| DE69503769T2 (de) * | 1994-03-09 | 1998-12-03 | Pfizer Inc., New York, N.Y. | Isoxazoline verbindung zur hemmung tnf-freigabe |
| US5610198A (en) * | 1994-03-18 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US6518281B2 (en) | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| NZ334148A (en) | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
| HUP0003761A3 (en) | 1997-07-31 | 2001-04-28 | Celgene Corp Warren | Substituted alkanohydroxamic acids and pharmaceutical compositions containing them |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| KR100620404B1 (ko) * | 2000-08-09 | 2006-09-13 | 파나세아 바이오테크 리미티드 | 항결핵 약물의 신규 약제학적 조성물 및 그의 제조방법 |
| AU2003222034A1 (en) | 2002-03-20 | 2003-10-08 | Celgene Corporation | (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| TW200501945A (en) * | 2002-11-06 | 2005-01-16 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| NZ540546A (en) | 2002-11-18 | 2008-03-28 | Celgene Corp | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| BR0317885A (pt) | 2002-12-30 | 2005-12-06 | Celgene Corp | Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa |
| JP2006519874A (ja) | 2003-03-05 | 2006-08-31 | セルジーン・コーポレーション | ジフェニルエチレン化合物およびその使用 |
| DE602004032522D1 (de) | 2003-03-12 | 2011-06-16 | Celgene Corp | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung |
| JP4713465B2 (ja) | 2003-03-12 | 2011-06-29 | セルジーン コーポレイション | ７−アミド−イソインドリル化合物およびその薬学的使用 |
| US7244259B2 (en) | 2003-10-31 | 2007-07-17 | Ethicon, Inc. | Guide for surgical device for the treatment of urinary incontinence |
| US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| KR20070092276A (ko) * | 2004-12-13 | 2007-09-12 | 셀진 코포레이션 | Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도 |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
-
2010
- 2010-02-09 EP EP10704460A patent/EP2395995A1/en not_active Withdrawn
- 2010-02-09 EA EA201171035A patent/EA201171035A1/ru unknown
- 2010-02-09 KR KR1020117021146A patent/KR20110116049A/ko not_active Ceased
- 2010-02-09 MX MX2011008132A patent/MX2011008132A/es active IP Right Grant
- 2010-02-09 MY MYPI2011003673A patent/MY160002A/en unknown
- 2010-02-09 AP AP2011005849A patent/AP3437A/xx active
- 2010-02-09 CN CN2010800159215A patent/CN102387798A/zh active Pending
- 2010-02-09 PE PE2011001445A patent/PE20120580A1/es not_active Application Discontinuation
- 2010-02-09 WO PCT/US2010/023533 patent/WO2010093588A1/en not_active Ceased
- 2010-02-09 SG SG2011054129A patent/SG173149A1/en unknown
- 2010-02-09 CA CA2750123A patent/CA2750123A1/en not_active Abandoned
- 2010-02-09 PE PE2015000636A patent/PE20151143A1/es not_active Application Discontinuation
- 2010-02-09 EP EP14170043.5A patent/EP2818164A1/en not_active Withdrawn
- 2010-02-09 US US13/148,659 patent/US20120149716A1/en not_active Abandoned
- 2010-02-09 SG SG10201402158VA patent/SG10201402158VA/en unknown
- 2010-02-09 BR BRPI1007500A patent/BRPI1007500A2/pt not_active IP Right Cessation
- 2010-02-09 JP JP2011549315A patent/JP2012517441A/ja active Pending
- 2010-02-09 UA UAA201110844A patent/UA103791C2/uk unknown
- 2010-02-09 AU AU2010213936A patent/AU2010213936B2/en not_active Ceased
- 2010-02-09 NZ NZ594193A patent/NZ594193A/xx not_active IP Right Cessation
-
2011
- 2011-07-19 IL IL214176A patent/IL214176A/en not_active IP Right Cessation
- 2011-07-29 CR CR20110411A patent/CR20110411A/es unknown
- 2011-08-09 NI NI201100154A patent/NI201100154A/es unknown
- 2011-08-21 EC EC2011011295A patent/ECSP11011295A/es unknown
- 2011-09-09 CO CO11116668A patent/CO6410289A2/es not_active Application Discontinuation
-
2015
- 2015-04-13 JP JP2015081559A patent/JP2015164928A/ja active Pending
- 2015-06-30 HK HK15106201.5A patent/HK1205681A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2011005849A0 (en) | 2011-08-31 |
| AU2010213936A1 (en) | 2011-08-11 |
| US20120149716A1 (en) | 2012-06-14 |
| IL214176A (en) | 2016-09-29 |
| JP2012517441A (ja) | 2012-08-02 |
| AU2010213936B2 (en) | 2014-07-31 |
| HK1205681A1 (en) | 2015-12-24 |
| NZ594193A (en) | 2013-09-27 |
| SG10201402158VA (en) | 2014-07-30 |
| IL214176A0 (en) | 2011-08-31 |
| NI201100154A (es) | 2012-01-24 |
| WO2010093588A1 (en) | 2010-08-19 |
| ECSP11011295A (es) | 2011-09-30 |
| MY160002A (en) | 2017-02-15 |
| PE20151143A1 (es) | 2015-08-07 |
| BRPI1007500A2 (pt) | 2016-02-16 |
| MX2011008132A (es) | 2011-09-06 |
| AP3437A (en) | 2015-10-31 |
| CA2750123A1 (en) | 2010-08-19 |
| EA201171035A1 (ru) | 2012-02-28 |
| CN102387798A (zh) | 2012-03-21 |
| SG173149A1 (en) | 2011-08-29 |
| KR20110116049A (ko) | 2011-10-24 |
| PE20120580A1 (es) | 2012-05-23 |
| JP2015164928A (ja) | 2015-09-17 |
| EP2395995A1 (en) | 2011-12-21 |
| CO6410289A2 (es) | 2012-03-30 |
| EP2818164A1 (en) | 2014-12-31 |
| CR20110411A (es) | 2012-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011008132A (es) | Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis. | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| WO2005046318A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | |
| WO2012027065A3 (en) | Combination therapy for treatment of disease | |
| WO2005044178A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MXPA05004778A (es) | Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas. | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| WO2005105088A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12014501495B1 (en) | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| WO2007058990A3 (en) | Therapy using cytokine inhibitors | |
| IL178591A (en) | 4– (Amino) –2– (2,6 – Dioxo (3-piperidyl)) - Isoindulin – 1,3 – Dion for the treatment and management of myelodysplastic syndromes | |
| MX2007005040A (es) | Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central. | |
| WO2005039497A3 (en) | Methods and compositions comprising thalidomide for treatment of fibromyalgia | |
| WO2004041190A3 (en) | Composition for the treatment of macular degenration | |
| TW200503683A (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| WO2005046594A3 (en) | Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders | |
| MX2010005009A (es) | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HK1200731A1 (en) | Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy |